Breast cancer is the most prevalent malignancy among women worldwide, and the increasing number of survivors is due to advances in early diagnosis and treatment efficacy. Consequently, the risk of developing contralateral breast cancer (CBC) among these survivors has become a concern. While surgical intervention with lumpectomy is a widely used primary approach for breast cancer, post-operative breast asymmetry is a potential concern. Many women opt for symmetrizing reduction procedures to improve aesthetic outcomes and quality of life. However, despite careful radiological screening, there is a chance of accidentally finding CBC. To address this, tissue excised during symmetrizing surgery is examined pathologically. In some cases, CBC or in situ lesions have been incidentally discovered in these specimens, prompting a need for a more thorough examination. Resection in pieces and the absence of surgical marking and pathological inking of the margin have made it challenging to precisely identify tumor location and assess tumor size and margin status, hampering adjuvant treatment decisions. A new protocol introduced in July 2022 aims to enhance the precision of CBC diagnosis, allowing for tailored treatment plans, including re-excision, systemic adjuvant therapy, or radiation therapy.
乳腺癌是全球女性中最常见的恶性肿瘤，早期诊断与治疗效果的提升使得幸存者数量不断增加。随之而来的是，这些幸存者罹患对侧乳腺癌的风险日益受到关注。虽然保乳手术是乳腺癌广泛采用的主要治疗手段，但术后乳房不对称性可能成为潜在问题。许多女性选择对称性缩小手术以改善美学效果和生活质量。然而，即使经过细致的影像学筛查，仍存在意外发现对侧乳腺癌的可能性。为此，对称性手术中切除的组织需进行病理学检查。部分病例中，这些标本中偶然发现对侧乳腺癌或原位病变，提示需要更全面的检查。由于组织分块切除、缺乏手术标记及切缘病理染色，精确定位肿瘤位置、评估肿瘤大小及切缘状态面临挑战，进而影响辅助治疗决策。2022年7月推出的新方案旨在提升对侧乳腺癌诊断的精确性，从而制定个体化治疗方案，包括再次切除、全身辅助治疗或放射治疗。
Breast Cancer in the Tissue of the Contralateral Breast Reduction
肿瘤(癌症)患者之家